A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Folinic acid; Pemetrexed
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 18 Sep 2008 Actual end date is June 2008 as reported by ClinicalTrials.gov.
- 18 Sep 2008 Actual patient number is 37 as reported by ClinicalTrials.gov.
- 18 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.